HKSE - Delayed Quote HKD

SINO BIOPHARM (1177.HK)

Compare
2.820
-0.110
(-3.75%)
At close: January 28 at 12:08:04 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
26,199,409.000
26,199,409.000
26,026,164.000
26,861,356.000
23,647,224.000
Cost of Revenue
4,989,877.000
4,989,877.000
4,487,616.000
5,332,095.000
5,182,320.000
Gross Profit
21,209,532.000
21,209,532.000
21,538,548.000
21,529,261.000
18,464,904.000
Operating Expense
15,423,818.000
15,423,818.000
16,058,744.000
17,175,600.000
14,160,755.000
Operating Income
5,785,714.000
5,785,714.000
5,479,804.000
4,353,661.000
4,304,149.000
Net Non Operating Interest Income Expense
-308,562.000
-308,562.000
-233,586.000
-146,560.000
-129,365.000
Pretax Income
5,409,906.000
5,409,906.000
5,214,869.000
18,572,673.000
5,013,044.000
Tax Provision
797,267.000
797,267.000
696,716.000
1,957,880.000
672,377.000
Net Income Common Stockholders
2,543,134.000
2,543,134.000
2,311,200.000
14,125,901.000
2,771,086.000
Average Dilution Earnings
211,195.000
--
-232,370.000
-482,511.000
--
Diluted NI Available to Com Stockholders
2,543,134.000
2,543,134.000
2,311,200.000
14,125,901.000
2,771,086.000
Basic EPS
0.13
0.13
0.14
0.78
0.15
Diluted EPS
0.13
0.13
0.12
0.73
0.15
Basic Average Shares
18,529,064.920
18,529,064.920
18,622,248.991
18,768,649.757
18,800,284.155
Diluted Average Shares
18,575,080.430
18,575,080.430
19,017,201.976
19,282,955.090
18,800,284.155
Rent Expense Supplemental
139,878.000
139,878.000
116,657.000
--
--
Total Expenses
20,413,695.000
20,413,695.000
20,546,360.000
22,507,695.000
19,343,075.000
Net Income from Continuing & Discontinued Operation
2,331,939.000
2,331,939.000
2,543,570.000
14,608,412.000
2,771,086.000
Normalized Income
1,887,083.857
1,887,083.857
2,403,020.890
14,860,393.598
2,383,158.635
Interest Income
186,675.000
186,675.000
195,908.000
162,057.000
194,003.000
Interest Expense
495,237.000
495,237.000
429,494.000
308,617.000
323,368.000
Net Interest Income
-308,562.000
-308,562.000
-233,586.000
-146,560.000
-129,365.000
EBIT
5,905,143.000
5,905,143.000
5,644,363.000
18,881,290.000
5,336,412.000
EBITDA
6,979,427.000
6,979,427.000
6,691,347.000
19,873,846.000
6,991,248.000
Reconciled Cost of Revenue
4,989,877.000
4,989,877.000
4,487,616.000
5,332,095.000
5,182,320.000
Reconciled Depreciation
1,074,284.000
1,074,284.000
1,046,984.000
992,556.000
1,654,836.000
Net Income from Continuing Operation Net Minority Interest
1,847,180.000
1,847,180.000
2,059,105.000
14,608,412.000
2,771,086.000
Total Unusual Items Excluding Goodwill
-46,801.000
-46,801.000
-396,949.000
-281,675.000
448,018.000
Total Unusual Items
-46,801.000
-46,801.000
-396,949.000
-281,675.000
448,018.000
Normalized EBITDA
7,026,228.000
7,026,228.000
7,088,296.000
20,155,521.000
6,543,230.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-6,897.143
-6,897.143
-53,033.110
-29,693.402
60,090.635
12/31/2020 - 5/12/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2269.HK WuXi Biologics (Cayman) Inc.
18.420
-0.22%
 
9926.HK Akeso, Inc.
60.850
+1.76%
 
6855.HK Ascentage Pharma Group International
33.950
-3.00%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
159.300
-0.62%
 
1548.HK GENSCRIPT BIO
10.680
+1.33%
 
1BT.F Enlivex Therapeutics Ltd.
1.0700
-0.93%
 
F6T.MU Fate Therapeutics Inc
1.2810
0.00%
 
1GDA.F Zevra Therapeutics, Inc.
7.45
-5.10%
 
HQ1.MU Oruka Therapeutics Inc. R
11.20
0.00%
 
GYX.F Futura Medical plc
0.3440
+1.18%